3 Disruptive Healthcare Stocks That Could Surge 1000% By 2028

Stocks to buy

The healthcare industry is experiencing extraordinary rapid terrain evolution as advancement meets necessity. Investors are focusing on disruptive businesses during this wave of change. These companies have the potential to transform the industry and provide exceptional returns. The edge of innovation and technology transcends the limits of traditional care, making healthcare more than just a service. Hence, three companies reshape the parameters of healthcare delivery.

The first one, a shining example of accessible and individualized care, experienced a sharp increase in its subscriber base. This demonstrates the growing need for affordable healthcare options. In the meantime, the second one is lowering obstacles to healthcare access and accelerating revenue development with its focus on virtual treatment and worldwide expansion. The third proves its endurance and flexibility in a fast-changing healthcare sector. The company is emerging as a powerhouse in retail healthcare with its varied portfolio, including pharmacy, healthcare plans and services.

Uncover the possibilities and possible benefits these revolutionary healthcare businesses provide investors and patients.

Hims & Hers (HIMS)

The logo for Hims & Hers (HIMS) displayed on a smartphone screen.

Source: Lori Butcher / Shutterstock.com

The number of subscribers to Hims & Hers (NYSE:HIMS) has strongly increased. This signifies the high market demand for the company’s health and wellness platform. In 2023, the company had 1.5 million subscribers, a boost of 48% year-over-year (YoY). The sharp increase in subscriptions highlights the efficacy of Hims & Hers’ strategies in drawing and attaching users to its platform.

In addition, the company has a lead in drawing in new customers and keeping hold of current ones. The company emphasizes providing a differentiated customer experience and growing its range of tailored services. Hence, these solutions focus on key specializations, including dermatology, mental health and weight reduction.

Throughout 2023, Hims & Hers had a top-line solid growth pattern, highlighting the company’s potential for rapid expansion. 2023, the company’s sales increased by 65% YoY to $872 million. This significant revenue growth indicates how successfully the company’s client attraction and sales-driven tactics work throughout its health and wellness platform.

Lastly, Hims & Hers projects revenue for 2024 to be between $1.17 billion and $1.20 billion, which would be a significant YoY boost. 

Teladoc Health (TDOC)

Teladoc Health (TDOC) logo on a mobile phone screen

Source: Piotr Swat / Shutterstock.com

Upsells and expansions account for over 75% of bookings at Teladoc Health (NYSE:TDOC). The company has found great success in cross-selling and upselling to its current clientele. This demonstrates how the business can use its sizable installed base of around 90 million virtual care subscribers and how it uses ongoing client interactions to generate incremental revenue.

Additionally, Teladoc Health’s attempts to expand internationally have paid off. The company’s overseas revenue rose 19% for 2023 and 15% in Q4. Further, the company has increased market penetration and aspirations for worldwide expansion, as demonstrated by its growing presence in other markets, especially in English-speaking nations like the UK and Canada.

Furthermore, Teladoc Health has continued to engage in innovation and expansion. Meanwhile, it is placing a high priority on cost-cutting and efficiency-boosting measures that boost bottom-line performance. The business has identified actions estimated to result in about $85 million in total annual savings on run-rate operating expenses through operational efficiency and optimization measures by the end of 2024. 

These cost-cutting strategies improve profitability and resource allocation for growth-oriented initiatives by reducing non-core spending, improving personnel management and simplifying administrative procedures.

CVS Health (CVS)

The front sign for a CVS Pharmacy, CVS stock

Source: Susan Montgomery / Shutterstock.com

With its several segments, CVS Health (NYSE:CVS) has a diverse top line. CVS Health provides millions of people with insurance products, such as Medicare Advantage and commercial plans, within the healthcare benefits segment. The business had a noteworthy gain in sales, with Q4 revenues coming in at around $27 billion, up more than 16% YoY. Strong enrollment periods, focused investments and membership expansion drive this development.

The health services segment also includes companies that provide healthcare delivery and pharmaceutical services to meet various healthcare requirements. In Q4, this segment’s revenues surpassed $49 billion, indicating a substantial YoY increase of over 12%. Moreover, this expansion was facilitated by acquisitions such as Oak Street and Signify Health. This has increased CVS Health’s capacity to provide pharmacy services and healthcare.

Finally, the pharmacy and consumer wellness segments cater to a sizable clientele by offering pharmaceutical goods, wellness programs and vaccinations by offering pharmaceutical goods, wellness programs and vaccinations. Notwithstanding obstacles, including pressure on reimbursements and shop closures, this segment’s sales increased by more than 9% in Q4 to above $31 billion. Therefore, higher prescription volumes and sharp operational performance facilitated this expansion.

On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.

Articles You May Like

3 Overvalued Tech Stocks Heading for a Fall
3 Cloud Computing Stocks to Sell in July Before They Crash & Burn
An Upcoming Stock Split Doesn’t Make Broadcom Stock a Buy
3 Plant-Based Food Stocks to Sell in July Before They Crash & Burn
Tesla Stock Price Predictions: What It Will Take for TSLA to Retake $300